glp 1 physiology informs the pharmacotherapy of obesity GLP-1-based therapies for diabetes, and beyond GLP-1 physiology in obesity and

10.1007/s10787-023-01373-z 140 Mohd-NorN

"Clinical review: Drugs commonly associated with weight change: a systematic review and meta-analysis"

DMSO can interfere with certain biological assays and is not recommended unless aqueous reconstitution fails after troubleshooting

consider calcifediol when faster repletion or persistent SHPT is relevant), avoid mega-bolus dosing, and reserve active VDRAs for clear SHPT indications with careful calciumphosphatePTH monitoringnot as disease-modifying therapy in unselected CKD

These help your provider monitor your metabolic health, check for any adverse effects, and adjust your treatment plan as needed